



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** John F. Braganza, et al.

**Examiner:** Unassigned

**Serial No.:** 10/776,953

**Art Unit:** Unassigned

**Filed:** February 11, 2004

**Docket:** 17390 (PC25332A)

**For:** NOVEL TRIAZOLO-PYRIDINES  
AS ANTI-INFLAMMATORY COMPOUNDS

**Dated:** August 12, 2004

**Confirmation No.:** 7596

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. United States Patent No. 3,050,525 dated August 21, 1962 to John B. Bicking;
2. Zhou L. et al., "Inhibition of the CD40 Pathway of Monocyte Activation by Triazolopyrimidine", *Clinical Immunology* 93(3):232-238 (1999);
3. International Patent Publication No. WO 01/57038 A1, published August 9, 2001; and
4. International Publication No. WO 03/044021 A2, published May 30, 2003.

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450.


Dated: August 12, 2004

  
Peter I. Bernstein

The references were cited in a Search Report dated May 7, 2004 received from the European Patent Office. Applicants are submitting copies of the above-cited references, together with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report. However, in accordance with the waiver of 37 C.F.R. § 1.98 (a)(2)(i) in effect as of June 30, 2003, Applicants are not required to submit a copy of the above-cited U.S. Patent reference.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Peter I. Bernstein  
Registration No.: 43,497

Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

PIB:dg

IFW

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))				<b>Docket No.</b> 17390 (PC25332A)	
In Re Application Of: <b>John Frederick Braganza, et al.</b>					
<b>Application No.</b> 10/776,953	<b>Filing Date</b> February 11, 2004	<b>Examiner</b> Unassigned	<b>Customer No.</b> 23389	<b>Group Art Unit</b> Unassigned	<b>Confirmation No.</b> 7596
<b>Title: NOVEL TRIAZOLE-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS</b>					
<p style="text-align: center;">Address to: <b>Commissioner for Patents</b> <b>P.O. Box 1450</b> <b>Alexandria, VA 22313-1450</b></p> <p style="text-align: center;"><b>37 CFR 1.97(b)</b></p> <p>1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.</p> <p style="text-align: center;"><b>37 CFR 1.97(c)</b></p> <p>2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:</p> <p style="padding-left: 40px;"><input type="checkbox"/> the statement specified in 37 CFR 1.97(e);</p> <p style="text-align: center;"><b>OR</b></p> <p style="padding-left: 40px;"><input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).</p>					

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
17390 (PC25332A)

In Re Application: John Frederick Braganza, et al.

AUG 16 2004

Application No. 10/776,953	Filing Date February 11, 2004	Examiner Unassigned	Customer No. 23389	Group Art Unit Unassigned	Confirmation No. 7596
-------------------------------	----------------------------------	------------------------	-----------------------	------------------------------	--------------------------

**NOVEL TRIAZOLE-PYRIDINES AS ANTI-INFLAMMATORY COMPOUNDS**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account **19-1013/SSMP** as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_).


\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**


I certify that this document and ~~fee~~ is being deposited on **8/12/04** th the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Signature of Person Mailing Correspondence

Peter I. Bernstein

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.

  
Signature

Dated: August 12, 2004

Peter I. Bernstein  
Registration No. 43,497  
Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, New York 11530  
516-742-4343

PIB:dg

CC:

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

AUG 16 2004

Docket Number (Optional)

17390 (PC25332A)

Application Number

10/776,953

Applicant(s)

John Frederick Braganza, et al.

Filing Date

February 11, 2004

Group Art Unit

Unassigned

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		3,050,525	8/21/62	John B. Bicking			

## U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		WO 01/57038 A1	8/9/01	PCT			
		WO 03/044021 A2	5/30/03	PCT			

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

		Zhou L. et al., "Inhibition of the CD40 Pathway of Monocyte Activation by Triazolopyrimidine", Clinical Immunology 93(3):232-238 (1999)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.